Mindset Pharma Announces Closing of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October 19, 2023, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through its wholly-owned subsidiary Otsuka America, Inc. ("OAI") has acquired all of the issued and outstanding common shares (each, a "Common Share") in the capital of the Company pursuant...
2023-10-27 7:00 AM EDT
Mindset Pharma Announces Receipt of Final Order
Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5, 2023, and October 19, 2023, the Company has obtained the final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Plan of Arrangement") under Division 5 of Part 9 of the Business...
2023-10-25 6:59 PM EDT
Mindset Pharma Announces Shareholder Approval of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 19, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023, that the special resolution (the "Special Resolution") in connection with their previously announced statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under...
2023-10-19 5:00 PM EDT
Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") wishes to clarify certain disclosure in its management information circular (the "Circular") dated September 19, 2023 for its special meeting of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under...
2023-10-05 5:15 PM EDT
Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order
Toronto, Ontario--(Newsfile Corp. - September 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related materials were mailed today, September 22, 2023, for its special meeting (the "Meeting") of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among...
2023-09-22 5:15 PM EDT
Otsuka Pharmaceutical to Acquire Mindset Pharma
Toronto, Ontario--(Newsfile Corp. - August 31, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, announce that they have entered into a definitive arrangement agreement (the "Agreement") pursuant to which Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through its wholly- owned...
2023-08-31 7:30 AM EDT
Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder
Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the "MHRA") and the Research Ethics Committee...
2023-06-22 9:06 AM EDT
Mindset Pharma Announces Grant of Options
Toronto, Ontario--(Newsfile Corp. - February 3, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has granted an aggregate of 6,065,000 options to purchase common shares of the Company to directors, officers and consultants of the Company, exercisable at a price of $0.275 per common share for a period of five (5) years from the date of grant, in accordance with the terms of the Company's stock option plan. The common...
2023-02-03 5:20 PM EST
Mindset Announces Participation at Upcoming Events in June 2021
Toronto, Ontario--(Newsfile Corp. - June 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that James Lanthier, CEO of Mindset, will participate in two upcoming events in June 2021:Benzinga Cannabis Capital Conference to be held virtually on...
2021-06-01 7:00 AM EDT
Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - May 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has been invited to present at the Canaccord Genuity 41st Annual Growth Conference being held August 10-12, 2021.James Lanthier, CEO of Mindset, commented, "Mindset is pleased to be invited to present at Canaccord Genuity's Growth Conference. Mindset is at the forefront of the biggest opportunity in the nascent psychedelic...
2021-05-05 7:00 AM EDT
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds
Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that certain of Mindset's Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics. James Lanthier, CEO of Mindset, commented, "N,N-dimethyltryptamine (DMT) & 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent,...
2021-04-29 7:00 AM EDT
Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services
Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has entered into an agreement with KCSA Strategic Communications ("KCSA") to provide investor relations services effective as of May 15, 2021. KCSA is a fully integrated communications consultancy with a creative and strategic approach to public relations, investor relations and social media. Mindset's agreement with KCSA has an initial...
2021-04-28 7:00 AM EDT
Mindset Pharma Invited to Present at H.C. Wainwright "Psychedelics in Psychiatry and Beyond" Virtual Conference
Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has been invited to present at the H.C. Wainwright "Psychedelics In Psychiatry and Beyond" Virtual Conference being held on June 17, 2021.James Lanthier, CEO of Mindset, commented, "Mindset is pleased to be invited to present at H.C. Wainwright's conference. Mindset has expanded its next generation drug program to four...
2021-04-26 10:31 AM EDT
Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio
Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce, that based on data derived from Mindset's in vivo testing program (i.e. testing in animal subjects) carried out by InterVivo Solutions Inc., the Company has confirmed that the majority of its patent pending compounds across four families of chemical scaffolds are exhibiting favourable effects in vivo in models established as...
2021-04-20 7:00 AM EDT
Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million
Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that in connection with its previously announced "bought deal" public offering (the "Offering") underwritten by Canaccord Genuity Corp. (the "Lead Underwriter"), as lead underwriter and sole bookrunner, along with Stifel Nicolaus Canada Inc. and Cormark Securities Inc. (collectively with the Lead Underwriter, the "Underwriters"),...
2021-04-19 9:36 AM EDT
Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering
Toronto, Ontario--(Newsfile Corp. - April 15, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that it has completed the previously announced "bought deal" public offering through the issuance of an aggregate of 10,000,000 units (each, a "Unit") of the Company at a price of $0.75 per Unit (the "Issue Price") for aggregate gross proceeds to the Company of $7,500,000 (the "Offering"). The Units were issued and sold pursuant to...
2021-04-15 9:10 AM EDT
Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020
Toronto, Ontario--(Newsfile Corp. - April 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company") - Mindset announces that it has refiled its interim financial statements for the three and six month period ended December 31, 2020 (the "Financial Statements") and accompanying management discussion and analysis (the "MD&A") as they have been restated to reflect certain adjustments resulting from a review by the Company's auditors.The following...
2021-04-01 10:28 PM EDT
Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik Slassi as Senior Vice President of Innovation in a full time capacity and the...
2021-03-30 7:00 AM EDT
Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set
Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. ("InterVivo" or "IVS"), to co-develop a new translational testing platform that Mindset and InterVivo expect will introduce an industry standard...
2021-03-23 8:59 AM EDT
Mindset Pharma Announces DTC Eligibility for OTCQB(R) Venture Listing
Toronto, Ontario--(Newsfile Corp. - March 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company ("DTC") for electronic settlement and transfer of its common shares in the United States. The Company's common...
2021-03-17 7:00 AM EDT